Comera Life Sciences 

$0.000100
4
+$0.00+0% Tuesday 20:00

Statistics

Day High
0.0001
Day Low
0.0001
52W High
0.0002
52W Low
0.0001
Volume
730
Avg. Volume
918
Mkt Cap
3,073.8
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

14NovExpected
Q1 2021
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Q3 2022
-1.14
-0.65
-0.17
0.32
Expected EPS
N/A
Actual EPS
-0.2

Financials

-3,266.08%Profit Margin
Unprofitable
2021
2022
1.03MRevenue
-33.68MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow CMRA. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Pfizer
PFE
Mkt Cap159.36B
Pfizer is a global pharmaceutical company that competes with Comera Life Sciences in the development and commercialization of biologics and biosimilars, which are core to Comera's business model.
Merck
MRK
Mkt Cap366B
Merck operates in the pharmaceutical and biopharmaceutical sectors, directly competing with Comera Life Sciences in the research, development, and marketing of drugs in similar therapeutic areas.
Johnson & Johnson
JNJ
Mkt Cap645.95B
Johnson & Johnson, through its pharmaceutical segment, competes with Comera Life Sciences in developing innovative treatments, including biologics, across various healthcare fields.
AMGEN
AMGN
Mkt Cap233.78B
Amgen focuses on human therapeutics, including biologics, in areas overlapping with Comera Life Sciences' interests, making it a direct competitor in the biopharmaceutical market.
Bristol-Myers Squibb
BMY
Mkt Cap136B
Bristol Myers Squibb is involved in discovering, developing, and delivering innovative medicines, including biologics, that compete with Comera Life Sciences' product offerings.
Abbvie
ABBV
Mkt Cap451.46B
AbbVie operates in the biopharmaceutical field, focusing on developing and marketing advanced therapies that compete with Comera Life Sciences' research and development in biologics.
Novartis
NVS
Mkt Cap292.35B
Novartis is a global healthcare company that competes with Comera Life Sciences in the development and marketing of patented pharmaceuticals, including biologics and biosimilars.
Roche
RHHBY
Mkt Cap334.28B
Roche Holding AG, through its pharmaceuticals division, competes in the biotechnology and biopharmaceutical sectors, directly challenging Comera Life Sciences in the biologics market.
Sanofi
SNY
Mkt Cap107.39B
Sanofi is a global biopharmaceutical company focusing on human health, directly competing with Comera Life Sciences in the development of biologics and specialty care products.
Gilead Sciences
GILD
Mkt Cap180.64B
Gilead Sciences is a biopharmaceutical company that develops and markets innovative therapeutics in areas of unmet medical need, competing with Comera Life Sciences in the biologics space.

About

Comera Life Sciences Holdings, Inc. is an early-stage biotechnology firm focused on creating its own pipeline of innovative therapies. These treatments leverage its exclusive SQore formulation platform, engineered to transform intravenous (IV) biologic drugs into more convenient subcutaneous (SQ) injectable forms. Currently, the company is progressing two main product candidates: CLS-001, an early-stage "biobetter" designed to treat inflammatory bowel conditions like Crohn's and Ulcerative Colitis, and CLS-002, another preclinical biobetter aimed at diverse oncology indications. Established in 2014, Comera Life Sciences is headquartered in Woburn, Massachusetts.
Show more...
CEO
Michael G. Campbell
Employees
12
Country
United States
ISIN
US20037C1080

Listings

0 Comments

Share your thoughts

FAQ

What is Comera Life Sciences stock price today?
The current price of CMRA is $0.00 USD — it has increased by +0% in the past 24 hours. Watch Comera Life Sciences stock price performance more closely on the chart.
What is Comera Life Sciences stock ticker?
Depending on the exchange, the stock ticker may vary. For instance, on OTC Link exchange Comera Life Sciences stocks are traded under the ticker CMRA.
Is Comera Life Sciences stock price growing?
CMRA stock has risen by +0% compared to the previous week, the month change is a +0% rise, over the last year Comera Life Sciences has showed a -50% decrease.
What is Comera Life Sciences market cap?
Today Comera Life Sciences has the market capitalization of 3,073.8
What were Comera Life Sciences earnings last quarter?
CMRA earnings for the last quarter are -0.2 USD per share, whereas the estimation was N/A USD resulting in a N/A surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Comera Life Sciences revenue for the last year?
Comera Life Sciences revenue for the last year amounts to 1.03M USD.
What is Comera Life Sciences net income for the last year?
CMRA net income for the last year is -33.68M USD.
How many employees does Comera Life Sciences have?
As of September 04, 2026, the company has 12 employees.
In which sector is Comera Life Sciences located?
Comera Life Sciences operates in the Health & Wellness sector.
When did Comera Life Sciences complete a stock split?
The last stock split for Comera Life Sciences was on May 21, 2003 with a ratio of 1:800.
Where is Comera Life Sciences headquartered?
Comera Life Sciences is headquartered in Woburn, United States.